Prediction of adverse cardiac events in dilated cardiomyopathy using cardiac T2* MRI and MIBG scintigraphy

International Journal of Cardiovascular Imaging

Volumn 31, Issue 2, 2015, Pages 399-407

  Nagao, Michinobu ^a   Baba, Shingo ^a   Yonezawa, Masato ^a   Yamasaki, Yuzo ^a   Kamitani, Takeshi ^a   Isoda, Takuro ^a   Kawanami, Satoshi ^a   Maruoka, Yasuhiro ^a   Kitamura, Yoshiyuki ^a   Abe, Kohtaro ^a   Higo, Taiki ^a   Sunagawa, Kenji ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Dilated cardiomyopathy; Major adverse cardiac event; MIBG scintigraphy; T2* MRI

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM PENTETATE MEGLUMINE; (3 IODOBENZYL)GUANIDINE; IRON; RADIOPHARMACEUTICAL AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GAMMA CAMERA; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HEART VENTRICLE SEPTUM; HUMAN; IRON DEFICIENCY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; SYMPATHETIC TONE; ADRENERGIC SYSTEM; CARDIOMYOPATHY, DILATED; COMPLICATION; DEFICIENCY; DISEASE COURSE; DISEASE FREE SURVIVAL; HEART; HEART MUSCLE; INNERVATION; JAPAN; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADULT; AREA UNDER CURVE; CARDIOMYOPATHY, DILATED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEART; HUMANS; IRON; JAPAN; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84925521923     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-014-0562-1     Document Type: Article

References (29)

1. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ (1992) The clinical course of idiopathic dilated cardiomyopathy: a population-based study. Ann Intern Med 117:117–123
2. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007
3. Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349–1355
4. Packer M, Coats AJ, Fowler MB et al (2001) Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658
5. Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41:233–243
6. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M (1998) Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252–1258
7. Merlet P, Valette H, Dubois-Rande JL et al (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477
8. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H (1997) ACE inhibition reduced cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38:1085–1089
9. Suwa M, Otake Y, Moriguchi A et al (1997) Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133:353–358
10. Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113:2454–2461
11. Groenveld HF, Januzzi JL, Damman K et al (2008) Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827
12. Doi T, Nakata T, Hashimoto A et al (2012) Cardiac mortality assessment improved by evaluation of cardiac sympathetic nerve activity in combination with hemoglobin and kidney function in chronic heart failure patients. J Nucl Med 53:731–740
13. Cohn JN, Levine TB, Olivari MT et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823
14. Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853
15. Beshai JF, Grimm RA, Nagueh SF et al (2007) Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 357:2461–2471
16. Slaughter MS, Rogers JG, Milano CA et al (2009) Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361:2241–2251
17. Goldstein D, Zucker M, Pagani FD, Frazier OH (2006) Rotary ventricular assist devices. In: Kirklin JK, Frazier OH (eds) ISHLT monograph series: mechanical circulatory support. Elsevier, New York, pp 77–104
18. Nakata T, Miyamoto K, Doi A et al (1998) Cardiac death prediction and impaired cardiac sympathetic innervation assessed by metaiodobenzylguanidine in patients with failing and non-failing hearts. J Nucl Cardiol 5:579–590
19. VanderVeen BJ, Younis I, DeRoos A, Stokkel M (2012) Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions. J Nucl Cardiol 19:752–760
20. Kirk P, He T, Anderson LJ, Roughton M et al (2010) International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 32:315–319
21. Reeder SB, Faranesh AZ, Boxerman JL, McVeigh ER (1998) In vivo measurement of T2* and field inhomogeneity maps in the human heart at 1.5T. Magn Reson Med 39:988–998
22. Andrews NC (2008) Forging a field: the golden age of iron biology. Blood 112:219–230
23. Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I-metaiodobenzylguanidine. J Nucl Med 21:349–353
24. Eisenhofer G, Friberg P, Rundqvist B et al (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667–1676
25. Nakata T, Wakabayashi T, Nagahara D (2005) Assessment of cardiac innervation in heart failure and lethal arrhythmias: therapeutic and prognostic implications. Curr Cardiol Rev 1:29–36
26. Nishisato K, Hashimoto A, Nakata T et al (2010) Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med 51:1241–1249
27. Jacobson AF, Senior R, Cerqueira MD et al (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in chronic heart failure: results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212–2221
28. Westwood MA, Anderson LJ, Firmin DN et al (2003) Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 18:616–620
29. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109:277–286